Skip to main content
IDNA Genomics Public Ltd (CYS:IDNA)
Cyprus flag Cyprus · Delayed Price · Currency is EUR
23.00
-0.20 (-0.86%)
At close: Mar 6, 2026

IDNA Genomics Public Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023
Period Ending
 Jun '25 Dec '24 Dec '23
Revenue
0.510.480.49
Revenue Growth (YoY)
--3.01%-
Cost of Revenue
0.50.350.17
Gross Profit
0.010.130.32
Selling, General & Admin
1.751.671.54
Other Operating Expenses
-0.07-0.07-0.01
Operating Expenses
1.681.611.53
Operating Income
-1.67-1.48-1.2
Interest Expense
-0.19-0.15-0.13
Other Non Operating Income (Expenses)
0.01-0-0
EBT Excluding Unusual Items
-1.85-1.63-1.34
Impairment of Goodwill
-1.34-1.34-
Pretax Income
-3.19-2.97-1.34
Income Tax Expense
0.010.010.01
Earnings From Continuing Operations
-3.2-2.97-1.34
Minority Interest in Earnings
0.690.45-
Net Income
-2.51-2.52-1.34
Net Income to Common
-2.51-2.52-1.34
Shares Outstanding (Basic)
333
Shares Outstanding (Diluted)
333
EPS (Basic)
-0.91-0.91-0.49
EPS (Diluted)
-0.91-0.91-0.49
Free Cash Flow
-2.77-2.53-0.01
Free Cash Flow Per Share
-1.00-0.92-0.01
Gross Margin
1.99%27.22%65.56%
Operating Margin
-325.63%-309.19%-244.23%
Profit Margin
-489.80%-527.75%-272.77%
Free Cash Flow Margin
-540.44%-528.51%-2.62%
EBITDA
-1.64-1.31-1.12
EBITDA Margin
--274.54%-227.85%
D&A For EBITDA
0.030.170.08
EBIT
-1.67-1.48-1.2
EBIT Margin
---244.23%
Source: S&P Capital IQ. Standard template. Financial Sources.